share_log

Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target

Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target

康特菲茨傑對crinetics藥業繼續維持超配評級,維持90美元的目標股價
Benzinga ·  09/16 11:36  · 評級/大行評級

Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $90 price target.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論